We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.26 | 34.19 | 34.69 | 0.00 | 11:51:33 |
From Jun 2022 to Jun 2024
By Michael Susin
AstraZeneca PLC and Daiichi Sankyo Co. have said that their antibody drug Enhertu has been approved by the U.S. Food and Drug Administration to treat adult patients with metastatic non-small cell lung cancer, whose tumours have activating mutations, and have received previous therapy.
The pharmaceutical giant said the decision came based on the response rate of 57.7% in patients with HER2-mutant disease from a Phase 2 trial.
"Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial," AstraZeneca said.
Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 12, 2022 02:38 ET (06:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
